For Research Purposes Only

Research explained

GHK-Cu: Skin Research & Safety

Separate GHK-Cu skin and laboratory findings from clinical claims. Explore a primary skin-penetration study and the limits of extrapolating to injections.

By PurePeptideHub Research Team · Evidence updated

Editorial evidence update; independent clinical review pending. Editorial standards

Evidence depends on the formulation and route; topical findings do not establish injectable safety.

Evidence at a glance

Selected sources supporting this update. This is an editorial evidence summary, not a systematic review of every publication.

Study design, findings and limitations for GHK-Cu
Source and designWhat it supportsWhat it cannot establish
Hostynek et al., 2010: copper tripeptide and human skin

Laboratory study using human skin outside the body

Researchers measured copper penetration and retention through different skin layers.An ex vivo absorption experiment is not a clinical trial of wrinkle reduction, hair regrowth or injectable treatment.
FDA: injectable GHK-Cu

Regulatory safety assessment

FDA identifies potential immune reactions associated with aggregation and peptide impurities in injectable preparations.A topical or laboratory study does not resolve the safety of an injectable formulation.

What kind of evidence is being discussed?

GHK-Cu appears in laboratory research and topical skin-care discussions. These settings answer different questions. A study on isolated cells or skin can describe a process without showing a meaningful benefit in people using a finished product.

What the skin-penetration study measures

This experiment tested how copper from a tripeptide preparation moved through and remained in human skin samples. Its endpoint concerns penetration and retention, not a patient-visible treatment outcome. Formulation and the skin layer tested affect how the experiment should be interpreted.

Why route of administration matters

Topical application and injection create different exposures. Evidence for one route should not be presented as proof of the other route’s benefit or safety. Claims about injectable GHK-Cu need their own clinical and product-quality evidence.

Reading a cosmetic claim

Look for a study on the finished formulation, a comparison group, a relevant outcome and a meaningful follow-up period. Ingredient-level mechanisms should be labeled as mechanisms. A manufacturer’s testimonial or percentage-purity statement is not a substitute for that evidence.

Common questions

Does skin penetration prove that GHK-Cu reduces wrinkles?

No. Penetration is a different endpoint from a clinical change in wrinkles. The linked experiment should not be presented as a wrinkle-treatment trial.

Do topical studies establish the safety of GHK-Cu injections?

No. Route, formulation and exposure differ. Injectable safety requires evidence appropriate to the injectable product.

Continue your research

Educational information only. This page does not recommend a medicine, dose or injection protocol. Report a correction with its source.